Published in J Natl Cancer Inst on March 05, 2010
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med (2012) 7.47
Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst (2013) 4.37
Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol (2012) 4.22
Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut (2010) 4.01
Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol (2011) 2.90
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Colorectal cancer: a tale of two sides or a continuum? Gut (2012) 2.85
Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res (2012) 2.50
Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA (2011) 2.28
Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA (2013) 2.26
Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. Am J Epidemiol (2012) 2.07
Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res (2012) 1.95
Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol (2013) 1.95
Review Article: The Role of Molecular Pathological Epidemiology in the Study of Neoplastic and Non-neoplastic Diseases in the Era of Precision Medicine. Epidemiology (2016) 1.89
How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn (2012) 1.66
Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer (2014) 1.46
Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res (2013) 1.46
Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). PLoS One (2011) 1.32
Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. Nat Rev Clin Oncol (2012) 1.26
Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level. J Natl Cancer Inst (2012) 1.24
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene (2013) 1.23
Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses' health study. J Natl Cancer Inst (2012) 1.19
Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. Gut (2015) 1.17
Integrative cancer epidemiology--the next generation. Cancer Discov (2012) 1.16
Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol (2014) 1.16
Molecular pathological epidemiology gives clues to paradoxical findings. Eur J Epidemiol (2015) 1.16
Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. Int J Cancer (2011) 1.12
DNA methylation biomarkers: cancer and beyond. Genes (Basel) (2014) 1.11
A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. Am J Epidemiol (2013) 1.08
Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer (2012) 1.07
Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with β-catenin (CTNNB1) status. Cancer Res (2013) 1.06
Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma. Ann Surg Oncol (2014) 1.02
Statistical methods for studying disease subtype heterogeneity. Stat Med (2015) 1.01
Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis. J Natl Cancer Inst (2014) 1.00
Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol (2014) 0.98
Commentary: Lifestyle factors and colorectal cancer microsatellite instability--molecular pathological epidemiology science, based on unique tumour principle. Int J Epidemiol (2012) 0.98
Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies. Arch Surg (2012) 0.97
Survival Benefit of Exercise Differs by Tumor IRS1 Expression Status in Colorectal Cancer. Ann Surg Oncol (2015) 0.96
Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer. Cancer Epidemiol Biomarkers Prev (2013) 0.96
Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res (Phila) (2011) 0.95
Integration of molecular pathology, epidemiology and social science for global precision medicine. Expert Rev Mol Diagn (2015) 0.94
Proceedings of the second international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control (2015) 0.94
Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women. Cancer Epidemiol Biomarkers Prev (2012) 0.92
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst (2013) 0.92
Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype. Br J Cancer (2014) 0.91
Marine ω-3 polyunsaturated fatty acids and risk of colorectal cancer according to microsatellite instability. J Natl Cancer Inst (2015) 0.91
Phenotypic and tumor molecular characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with survival. Carcinogenesis (2012) 0.90
Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status. J Natl Cancer Inst (2015) 0.89
Potential role of gastrointestinal microbiota composition in prostate cancer risk. Infect Agent Cancer (2013) 0.86
TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers. PLoS One (2011) 0.86
Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. J Gastroenterol (2016) 0.86
Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia. Int J Mol Epidemiol Genet (2013) 0.85
A Meta-Regression Method for Studying Etiological Heterogeneity Across Disease Subtypes Classified by Multiple Biomarkers. Am J Epidemiol (2015) 0.85
Challenges and opportunities in international molecular cancer prevention research: An ASPO Molecular Epidemiology and the Environment and International Cancer Prevention Interest Groups Report. Cancer Epidemiol Biomarkers Prev (2014) 0.84
Postmenopausal hormone therapy is associated with a reduced risk of colorectal cancer lacking CDKN1A expression. Cancer Res (2012) 0.84
Can tissue-based immune markers be used for studying the natural history of cancer? Ann Epidemiol (2012) 0.83
Incident urothelial cancer in the Malmö Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker. Diagn Pathol (2014) 0.82
Characterizing the prevalence of chromosome instability in interval colorectal cancer. Neoplasia (2015) 0.81
The complexities of epidemiology and prevention of gastrointestinal cancers. Int J Mol Sci (2012) 0.81
Serrated polyps and their alternative pathway to the colorectal cancer: a systematic review. Gastroenterol Res Pract (2015) 0.81
FAS rs2234767 and rs1800682 polymorphisms jointly contributed to risk of colorectal cancer by affecting SP1/STAT1 complex recruitment to chromatin. Sci Rep (2016) 0.80
Origin, Methods, and Evolution of the Three Nurses' Health Studies. Am J Public Health (2016) 0.80
Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations. Oncotarget (2015) 0.79
Ogino et Al. Respond to "the 21st century epidemiologist". Am J Epidemiol (2012) 0.79
Predicted 25(OH)D score and colorectal cancer risk according to vitamin D receptor expression. Cancer Epidemiol Biomarkers Prev (2014) 0.79
KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients. Int J Mol Sci (2016) 0.79
Vitamin D and colorectal cancer: molecular, epidemiological and clinical evidence. Br J Nutr (2016) 0.78
Genome-wide linkage analysis and tumoral characterization reveal heterogeneity in familial colorectal cancer type X. J Gastroenterol (2014) 0.78
SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features. Ann Surg Oncol (2014) 0.77
SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing MGMT-Methylated Colorectal Cancer. Clin Cancer Res (2016) 0.76
Expression Pattern and Clinicopathological Relevance of the Indoleamine 2,3-Dioxygenase 1/Tryptophan 2,3-Dioxygenase Protein in Colorectal Cancer. Dis Markers (2016) 0.75
Vegetarianism, low meat consumption and the risk of lung, postmenopausal breast and prostate cancer in a population-based cohort study. Eur J Clin Nutr (2016) 0.75
Association of multiple genetic variants with breast cancer susceptibility in the Han Chinese population. Oncotarget (2016) 0.75
Association between prognostic survival of human colorectal carcinoma and ZNRF3 expression. Onco Targets Ther (2016) 0.75
Proceedings of the third international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control (2017) 0.75
Molecular pathological epidemiology in diabetes mellitus and risk of hepatocellular carcinoma. World J Hepatol (2016) 0.75
Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence. Sci Rep (2017) 0.75
Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. J Clin Oncol (2017) 0.75
Cancer subtypes in aetiological research. Eur J Epidemiol (2017) 0.75
Harmonisation of biobanking standards in endometrial cancer research. Br J Cancer (2017) 0.75
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med (2007) 9.04
Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93
Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology (2005) 6.34
Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med (1995) 5.42
Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst (2000) 4.39
Molecular classification and correlates in colorectal cancer. J Mol Diagn (2007) 3.25
Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst (2006) 3.08
Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One (2008) 2.92
Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst (2006) 2.77
AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes. J Biol Chem (1998) 2.38
Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut (2005) 2.37
Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer (2007) 2.36
Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. J Natl Cancer Inst (2010) 1.99
Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol (2008) 1.88
Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia (2007) 1.85
Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomarkers Prev (2009) 1.72
Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. Cancer Res (2007) 1.61
Dietary folate, alcohol and B vitamins in relation to LINE-1 hypomethylation in colon cancer. Gut (2009) 1.54
APC mutations and other genetic and epigenetic changes in colon cancer. Mol Cancer Res (2007) 1.54
Diet, lifestyle, and genomic instability in the North Carolina Colon Cancer Study. Cancer Epidemiol Biomarkers Prev (2005) 1.45
Body size and the risk of colon cancer in a large case-control study. Int J Obes Relat Metab Disord (1998) 1.41
Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res (2009) 1.39
Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev (2008) 1.36
Associations between dietary intake and Ki-ras mutations in colon tumors: a population-based study. Cancer Res (2000) 1.32
Risk of microsatellite-unstable colorectal cancer is associated jointly with smoking and nonsteroidal anti-inflammatory drug use. Cancer Res (2006) 1.31
Nicotine-induced activation of AMP-activated protein kinase inhibits fatty acid synthase in 3T3L1 adipocytes: a role for oxidant stress. J Biol Chem (2007) 1.29
Mismatch repair polymorphisms and risk of colon cancer, tumour microsatellite instability and interactions with lifestyle factors. Gut (2008) 1.26
Early life exposure to famine and colorectal cancer risk: a role for epigenetic mechanisms. PLoS One (2009) 1.21
Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res (2009) 1.20
Lifestyle factors and Ki-ras mutations in colon cancer tumors. Mutat Res (2001) 1.19
Somatic alterations, metabolizing genes and smoking in rectal cancer. Int J Cancer (2009) 1.17
Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Hum Pathol (2007) 1.15
High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target. Am J Gastroenterol (2009) 1.15
Dietary factors and microsatellite instability in sporadic colon carcinomas. Cancer Epidemiol Biomarkers Prev (2003) 1.12
Risk factors for Ki-ras protooncogene mutation in sporadic colorectal adenomas. Cancer Res (1999) 1.12
Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod Pathol (2008) 1.11
p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis. Cancer Epidemiol Biomarkers Prev (2009) 1.10
Folate and vitamin B6 intake and risk of colon cancer in relation to p53 expression. Gastroenterology (2008) 1.06
One-carbon metabolism and CpG island methylator phenotype status in incident colorectal cancer: a nested case-referent study. Cancer Causes Control (2009) 1.04
Obesity enhances gastrointestinal tumorigenesis in Apc-mutant mice. Int J Obes (Lond) (2008) 1.04
A cohort study of STMN1 expression in colorectal cancer: body mass index and prognosis. Am J Gastroenterol (2009) 1.03
A prospective study of dietary folate and vitamin B and colon cancer according to microsatellite instability and KRAS mutational status. Cancer Epidemiol Biomarkers Prev (2008) 1.03
A cohort study of p27 localization in colon cancer, body mass index, and patient survival. Cancer Epidemiol Biomarkers Prev (2009) 1.02
Alpha-1-antitrypsin deficiency and smoking as risk factors for mismatch repair deficient colorectal cancer: a study from the colon cancer family registry. Mol Genet Metab (2009) 0.95
Dietary fat and risk of colon and rectal cancer with aberrant MLH1 expression, APC or KRAS genes. Cancer Causes Control (2007) 0.92
Dietary folate intake and k-ras mutations in sporadic colon and rectal cancer in The Netherlands Cohort Study. Int J Cancer (2005) 0.86
Dietary folate and APC mutations in sporadic colorectal cancer. J Nutr (2006) 0.82
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med (2007) 9.04
Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med (2013) 7.72
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med (2012) 7.47
Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res (2011) 5.97
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst (2013) 4.37
The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One (2008) 4.32
Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol (2012) 4.22
Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med (2007) 3.55
Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature (2012) 3.54
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol (2010) 3.03
Low-carbohydrate diets and all-cause and cause-specific mortality: two cohort studies. Ann Intern Med (2010) 2.95
Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One (2008) 2.92
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Colorectal cancer: a tale of two sides or a continuum? Gut (2012) 2.85
PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia (2008) 2.82
A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology (2009) 2.56
Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst (2009) 2.53
Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res (2012) 2.50
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40
Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med (2011) 2.34
Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA (2011) 2.28
Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA (2013) 2.26
Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res (2012) 2.26
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw (2011) 2.24
Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells. J Mol Diagn (2010) 2.15
Genome-wide association study of glioma and meta-analysis. Hum Genet (2012) 1.96
Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res (2012) 1.95
Physical activity and male colorectal cancer survival. Arch Intern Med (2009) 1.95
Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut (2011) 1.94
Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia (2007) 1.85
Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci U S A (2009) 1.81
Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer. J Natl Cancer Inst (2013) 1.80
A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst (2012) 1.74
Evidence-based criteria in the nutritional context. Nutr Rev (2010) 1.68
Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst (2013) 1.63
STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res (2011) 1.62
Risk factors for mortality in the nurses' health study: a competing risks analysis. Am J Epidemiol (2010) 1.61
Dietary intake of fish, ω-3 and ω-6 fatty acids and risk of colorectal cancer: A prospective study in U.S. men and women. Int J Cancer (2014) 1.60
Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet (2013) 1.56
The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med (2009) 1.56
Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology (2010) 1.56
Dietary folate, alcohol and B vitamins in relation to LINE-1 hypomethylation in colon cancer. Gut (2009) 1.54
The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res (2006) 1.52
Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol Cancer (2010) 1.50
HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol (2010) 1.48
Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer (2010) 1.48
The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. Kidney Int (2003) 1.48
Consumption of fish products across the lifespan and prostate cancer risk. PLoS One (2013) 1.46
DNA methylation, field effects, and colorectal cancer. J Natl Cancer Inst (2005) 1.44
Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers--results from BPC3. PLoS One (2011) 1.41
Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia (2009) 1.39
Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res (2009) 1.39
NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol (2010) 1.38
The practice of science at its best. Fertil Steril (2003) 1.38
Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. J Mol Diagn (2012) 1.34
DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. Clin Cancer Res (2009) 1.33
Common genetic variants in prostate cancer risk prediction--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev (2012) 1.29
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov (2014) 1.26
Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: prospective cohort study. PLoS Med (2009) 1.26
Dietary protein sources and the risk of stroke in men and women. Stroke (2011) 1.23
Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. Cancer Res (2012) 1.23
Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res (2009) 1.20
Association between insomnia symptoms and mortality: a prospective study of U.S. men. Circulation (2013) 1.20
Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review. Int J Cancer (2011) 1.20
SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol (2009) 1.19
Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses' health study. J Natl Cancer Inst (2012) 1.19
Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol (2011) 1.16
MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Control (2010) 1.16
CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci. Mod Pathol (2008) 1.16
Associations between carcinogen-DNA damage, glutathione S-transferase genotypes, and risk of lung cancer in the prospective Physicians' Health Cohort Study. Carcinogenesis (2002) 1.16
The association between dietary patterns at midlife and health in aging: an observational study. Ann Intern Med (2013) 1.14
PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis (2009) 1.13
Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. Int J Cancer (2011) 1.12
CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. Int J Cancer (2010) 1.11
JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype. Neoplasia (2009) 1.10
Associations of self-reported sleep duration and snoring with colorectal cancer risk in men and women. Sleep (2013) 1.09
Prediagnostic plasma IgE levels and risk of adult glioma in four prospective cohort studies. J Natl Cancer Inst (2011) 1.09
The merits of subtyping obesity: one size does not fit all. JAMA (2013) 1.08
Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol (2013) 1.08
A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. Am J Epidemiol (2013) 1.08
Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med (2014) 1.07
Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer. Am J Pathol (2010) 1.07
Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer (2012) 1.07
Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst (2011) 1.06
Folate and vitamin B6 intake and risk of colon cancer in relation to p53 expression. Gastroenterology (2008) 1.06
Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with β-catenin (CTNNB1) status. Cancer Res (2013) 1.06
DNA degradation test predicts success in whole-genome amplification from diverse clinical samples. J Mol Diagn (2007) 1.05
Association between colorectal cancer susceptibility loci and survival time after diagnosis with colorectal cancer. Gastroenterology (2012) 1.05
Germline polymorphisms in the one-carbon metabolism pathway and DNA methylation in colorectal cancer. Cancer Causes Control (2010) 1.04
A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. J Clin Endocrinol Metab (2010) 1.04
A prospective study of dietary folate and vitamin B and colon cancer according to microsatellite instability and KRAS mutational status. Cancer Epidemiol Biomarkers Prev (2008) 1.03
Prognostic significance of MTOR pathway component expression in neuroendocrine tumors. J Clin Oncol (2013) 1.02
The role of epidemiology in the era of molecular epidemiology and genomics: Summary of the 2013 AJE-sponsored Society of Epidemiologic Research Symposium. Am J Epidemiol (2013) 1.02